Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow APVO
Aptevo Therapeutics Inc. (APVO) EV/Sales
As of 16 October 2026, Aptevo Therapeutics Inc. (APVO) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −153,269,937× (September 2017) to 997,998,880× (December 2017); the current reading is higher than 24% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 527,132× | (70.03%) |
| FY2021 | 1,759,122× | (67.78%) |
| FY2020 | 5,460,127× | 1,029.29% |
| FY2019 | 483,500× | (95.24%) |
| FY2018 | 10,164,405× | (82.08%) |
| FY2017 | 56,728,397× | 36.44% |
| FY2016 | 41,578,220× | (0.08%) |
| FY2015 | 41,611,621× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2022 | 1,308,023× | (25.64%) |
| Dec 2021 | 1,759,122× | (56.29%) |
| Sep 2021 | 4,024,367× | (36.80%) |
| Jun 2021 | 6,367,282× | (45.77%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DCOY Decoy Therapeutics Inc compare | −3.5× |
| EOCN Eocene Ltd. compare | −3.0× |
| ARAV ARAVIVE, INC compare | −0.4× |
| APVO Aptevo Therapeutics Inc. | −0.3× |
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 2.0× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 18.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)